| Name | Title | Contact Details |
|---|---|---|
Ashley Macha |
Director Marketing and Communication | Profile |
Christen Feiler |
Associate Director, Financial Operations | Profile |
John Vasellina |
Associate Director, Talent and Organization Development | Profile |
Elizabeth Herkelrath |
Vice President, Digital Product Management & Business Delivery | Profile |
Lawrence Lupkin |
Director, Operations and Finance -- Technology Development & Clinical Research Administration | Profile |
Inspyr Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of promising, new therapeutics. Our work is motivated by a commitment to innovation and helping patients. We combine our powerful insights and rigorous scientific methods to create new treatment options for patients.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.
NUCATS provides scientists with consultative resources and expertise in order to accelerate how quickly transformative scientific discoveries make their way to patients and the community. It is our goal to continually increase the quality, safety, efficiency and speed of innovative clinical and translational research.
Erchonia Medical is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Mckinney, TX. To find more information about Erchonia Medical, please visit www.erchonia.com
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.